Stockhead’s Ashtyn Hiron sits down with Optiscan (ASX:OIL) CEO and managing director Camile Farah to close the books on 2023 and gain a sneak peek into what’s around the corner.

“We hit quite a few of our milestones in relation to product development,” Farah said.

“We also raised some capital, $16.7 million, with the support of our shareholders. That has put in a very good stead for next year.”

Tune in to hear what’s coming up for Optiscan in 2024.

Read MoreMedtech

Featured Companies

You might be interested in